Anne S Strik

List of Publications by Year
in descending order

21 papers	683 citations	759055 12 h-index	887953 17 g-index
21 all docs	21 docs citations	21 times ranked	1044 citing authors

#	Article	IF	Citations
1	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scandinavian Journal of Gastroenterology, 2021, 56, 145-154.	0.6	61
2	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. Therapeutic Drug Monitoring, 2020, 42, 289-294.	1.0	13
3	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clinical Pharmacokinetics, 2019, 58, 15-37.	1.6	91
4	Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. Expert Review of Clinical Pharmacology, 2019, 12, 885-891.	1.3	8
5	Hemolytic anemia after switching from infliximab originator to biosimilar CTâ€P13 in a patient with inflammatory bowel disease: A case report. Clinical Case Reports (discontinued), 2019, 7, 2049-2053.	0.2	7
6	DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. Journal of Crohn's and Colitis, 2019, 13, S063-S063.	0.6	34
7	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology, 2019, 54, 700-706.	0.6	16
8	Higher anti-TNF serum levels are associated with perianal fistula closure in Crohnâ€™s disease patients. Scandinavian Journal of Gastroenterology, 2019, 54, 453-458.	0.6	49
9	Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumabâ€"Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1041-1042.	1.9	0
10	Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 404-412.	3.7	56
11	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. Therapeutic Drug Monitoring, 2018, 40, 202-211.	1.0	26
12	OP005 Higher anti-TNF serum levels are associated with perianal fistula closure in Crohnâ€™s disease patients. Journal of Crohn's and Colitis, 2018, 12, S004-S004.	0.6	0
13	Individualized Dosing of Therapeutic Monoclonal Antibodiesâ€"a Changing Treatment Paradigm?. AAPS Journal, 2018, 20, 99.	2.2	29
14	Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. The Cochrane Library, 2018, , .	1.5	0
15	Antigenic response to <scp>CT</scp>â€P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Alimentary Pharmacology and Therapeutics, 2018, 48, 507-522.	1.9	20
16	Suppression of antiâ€drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1128-1134.	1.9	106
17	Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 401-406.	1.4	7
18	Editorial: antiâ€tumour necrosis factor Î± antibodies â€" can efficacy be regained? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1474-1475.	1.9	0

#	Article	IF	Citations
19	A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 650-660.	0.9	116
20	Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study. Gastroenterology, 2017, 152, S66.	0.6	4
21	Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology, 2016, 9, 429-439.	1.3	40